Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Candidate Ebola vaccine still effective when highly diluted, macaque study finds

21.10.2019

Scientists hope findings mean vaccine supplies could stretch farther

A single dose of a highly diluted VSV-Ebola virus (EBOV) vaccine--approximately one-millionth of what is in the vaccine being used to help control the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC)--remains fully protective against disease in experimentally infected monkeys, according to National Institutes of Health scientists.


Ebola virus Makona covering the surface of an infected cell.

Credit: NIAID

The NIH investigators completed the vaccine dosage study using cynomolgus macaques and an updated vaccine component to match the EBOV Makona strain that circulated in West Africa from 2014-16. The study appears in Lancet's EBioMedicine.

Nearly 250,000 people have received the investigational VSV-EBOV vaccine since August 2018 as part of a "ring vaccination" program to help stem the outbreak. The vaccine appears to be safe and highly effective. The manufacturer has announced that it has submitted a biologics license application to the U.S. Food and Drug Administration.

VSV-EBOV is based on a live-attenuated vesicular stomatitis virus and delivers an EBOV protein to elicit protective immune responses. With the continued need to vaccinate individuals in the DRC and surrounding countries, a potential shortage of VSV-EBOV vaccine is a concern and further dose adjustment is a possible solution.

Scientists from NIH's Rocky Mountain Laboratories (RML), part of the National Institute of Allergy and Infectious Diseases, tested several dosage strengths, including one with 10 million plaque-forming units (PFU). They determined that a vaccine with 10 PFUs was just as effective as the highest dose tested (a dose which was still lower than the one currently in use in the DRC).

They vaccinated macaques 28 days prior to infecting them with a lethal dose of EBOV and then monitored the animals for 42 days after infection. Even the macaques given the lowest dose appeared completely protected from disease due to EBOV.

The scientists say their study findings could help make more vaccine available for more people and may reduce adverse reactions to the vaccine because of the smaller amount of active ingredient. Such reactions can include injection site irritation, headache, fatigue, fever, chills, myalgia, and arthralgia. Demonstrating that the vaccine appears effective with adjusted dosing also could ease the burden on vaccine production.

The authors say that although results from preclinical and clinical studies can differ, these promising findings in macaques of complete protection with a lower-dose VSV-EBOV vaccine help support the possibility of similar clinical trials in people.

###

ARTICLE: A Marzi et al. Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge. EBioMedicine DOI: 10.1016/j.ebiom.2019.09.055 (2019).

WHO: Heinz Feldmann, M.D., Ph.D., chief of NIAID's Laboratory of Virology, and Andrea Marzi, Ph.D., lead author, are available to comment on this study.

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

NIH...Turning Discovery Into Health®

Media Contact

Ken Pekoc
kpekoc@niaid.nih.gov
301-402-1663

 @NIAIDNews

http://www.niaid.nih.gov 

Ken Pekoc | EurekAlert!
Further information:
http://dx.doi.org/10.1016/j.ebiom.2019.09.055

Further reports about: Ebola Infectious Diseases NIAID NIH macaques medical research vaccination

More articles from Health and Medicine:

nachricht Protection for pacemakers
21.11.2019 | ETH Zurich

nachricht Rapid emergence of antibiotic resistance during standard therapy
21.11.2019 | Christian-Albrechts-Universität zu Kiel

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Machine learning microscope adapts lighting to improve diagnosis

Prototype microscope teaches itself the best illumination settings for diagnosing malaria

Engineers at Duke University have developed a microscope that adapts its lighting angles, colors and patterns while teaching itself the optimal...

Im Focus: Small particles, big effects: How graphene nanoparticles improve the resolution of microscopes

Conventional light microscopes cannot distinguish structures when they are separated by a distance smaller than, roughly, the wavelength of light. Superresolution microscopy, developed since the 1980s, lifts this limitation, using fluorescent moieties. Scientists at the Max Planck Institute for Polymer Research have now discovered that graphene nano-molecules can be used to improve this microscopy technique. These graphene nano-molecules offer a number of substantial advantages over the materials previously used, making superresolution microscopy even more versatile.

Microscopy is an important investigation method, in physics, biology, medicine, and many other sciences. However, it has one disadvantage: its resolution is...

Im Focus: Atoms don't like jumping rope

Nanooptical traps are a promising building block for quantum technologies. Austrian and German scientists have now removed an important obstacle to their practical use. They were able to show that a special form of mechanical vibration heats trapped particles in a very short time and knocks them out of the trap.

By controlling individual atoms, quantum properties can be investigated and made usable for technological applications. For about ten years, physicists have...

Im Focus: Images from NJIT's big bear solar observatory peel away layers of a stellar mystery

An international team of scientists, including three researchers from New Jersey Institute of Technology (NJIT), has shed new light on one of the central mysteries of solar physics: how energy from the Sun is transferred to the star's upper atmosphere, heating it to 1 million degrees Fahrenheit and higher in some regions, temperatures that are vastly hotter than the Sun's surface.

With new images from NJIT's Big Bear Solar Observatory (BBSO), the researchers have revealed in groundbreaking, granular detail what appears to be a likely...

Im Focus: New opportunities in additive manufacturing presented

Fraunhofer IFAM Dresden demonstrates manufacturing of copper components

The Fraunhofer Institute for Manufacturing Technology and Advanced Materials IFAM in Dresden has succeeded in using Selective Electron Beam Melting (SEBM) to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

First International Conference on Agrophotovoltaics in August 2020

15.11.2019 | Event News

Laser Symposium on Electromobility in Aachen: trends for the mobility revolution

15.11.2019 | Event News

High entropy alloys for hot turbines and tireless metal-forming presses

05.11.2019 | Event News

 
Latest News

Scientists first to develop rapid cell division in marine sponges

21.11.2019 | Life Sciences

First detection of gamma-ray burst afterglow in very-high-energy gamma light

21.11.2019 | Physics and Astronomy

Research team discovers three supermassive black holes at the core of one galaxy

21.11.2019 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>